Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
31 studies found for:    " November 14, 2012":" December 14, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
1 Completed An Evaluation of a Rapid Test for HIV
Condition: HIV Seropositivity
Intervention: Device: Rapid testing for HIV
2 Completed Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care
Condition: HIV Positive Youth That Are Newly Engaged in Care
Interventions: Behavioral: Project ACCEPT;   Behavioral: HEALTH
3 Withdrawn The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies
Condition: HIV Infections
Interventions: Behavioral: HIV Test Offer;   Behavioral: General Health Screen Offer
4 Terminated Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease
Condition: HIV Disease
Intervention: Biological: α1 Proteinase Inhibitor
5 Completed Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
Condition: HIV Infection
Interventions: Dietary Supplement: Vitamin D3 50,000 IU;   Dietary Supplement: Vitamin D3 placebo
6 Completed Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine
Condition: HIV
Interventions: Drug: Etravirine;   Drug: Darunavir/ritonavir;   Drug: artemether/lumefantrine
7 Active, not recruiting Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Condition: Human Immunodeficiency Virus
Interventions: Drug: Busulfan;   Biological: Cal-1 modified HSPC;   Biological: Cal-1 modified CD4+ T lymphocytes
8 Recruiting Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Children Infected With HIV and TB
Conditions: HIV Infections;   Tuberculosis
Intervention: Drug: Raltegravir
9 Unknown  Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum
Conditions: Malaria in Pregnancy;   HIV Infection
Interventions: Drug: cotrimoxazole daily prophylaxis;   Drug: sulphadoxine-pyrimethamine
10 Recruiting Neurocognitive Effects of Opiate Agonist Treatment
Conditions: Opioid-Related Disorders;   HIV;   HIV Infections
Interventions: Drug: Buprenorphine;   Drug: Methadone
11 Completed Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence
Conditions: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS);   Self-Directed Violence
Intervention:
12 Completed A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence
Condition: Acquired Immune Deficiency Syndrome
Intervention: Drug: No intervention
13 Completed A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista
Condition: Acquired Immune Deficiency Syndrome
Intervention: Drug: No intervention
14 Unknown  A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
Condition: HIV
Intervention: Drug: Darunavir, Ritonavir and Rilpivirine
15 Completed DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate
Condition: HIV
Interventions: Drug: dapivirine;   Drug: miconazole
16 Unknown  Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS
Condition: Veterans With HIV/AIDS Diagnosis.
Intervention:
17 Recruiting Does Rosuvastatin Delay Progression of Atherosclerosis in HIV
Conditions: HIV;   Cardiovascular Disease
Interventions: Drug: Rosuvastatin;   Other: Placebo
18 Withdrawn A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
Condition: Human Immunodeficiency Virus Infection
Interventions: Drug: amdoxovir 300 mg bid;   Drug: amdoxovir 500 mg bid
19 Completed Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
20 Completed
Has Results
Atorvastatin for HAART Suboptimal Responders
Condition: Acquired Immune Deficiency Syndrome Virus
Interventions: Other: atorvastatin, Lipitor®;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.